OGI’s Q1 2026 Earnings Ride U.S. THC Expansion — But Profits Stay in Question

Forward-Looking Analysis

Analysts project Organigram Global’s Q1 2026 revenue to exceed $80 million, driven by its U.S. THC beverage expansion into 25 states and new product launches like ‘happly’ THC gummies. Earnings per share (EPS) are forecasted to improve to -$0.15, reflecting cost-cutting measures and operational efficiencies. Alliance Global Partners raised its price target to C$4 from C$3.60 in December 2025, citing strong Q4 2025 results and 2026 guidance. Wall Street Zen upgraded OGI to “Hold” in December 2025, noting improved market positioning. However, Weiss Ratings maintains a “Sell (D)” rating, highlighting ongoing profitability challenges. No major analyst upgrades or downgrades were reported in the final month before the earnings date.

Historical Performance Review

Organigram Global’s Q4 2025 results showed revenue of $85.94 million, a net loss of $37.96 million, and an EPS of -$0.28. Gross profit totaled $31.84 million, reflecting margin improvements from cost optimization and higher-margin product mix. The quarter marked a record revenue milestone but underscored persistent profitability hurdles.

Additional News

In December 2025, Organigram appointed a new CEO to drive global growth, signaling a strategic shift. The company expanded its U.S. presence with hemp-derived THC beverage launches and direct-to-consumer sales in 25 states. A December 2025 report highlighted legal cannabis’s $16 billion contribution to Canada’s GDP in 2024, bolstering long-term growth narratives. Alliance Global Partners raised its price target to C$4 in December 2025, while Weiss Ratings reiterated a “Sell (D)” rating. No major M&A activity was reported in the final month before the earnings release.

Summary & Outlook

Organigram’s Q1 2026 earnings face upside potential from U.S. market expansion and leadership changes, though historical losses and profitability risks persist. Revenue growth is supported by new product categories and international partnerships, while EPS improvements hinge on cost discipline. The upgraded price target and CEO appointment signal optimism, but sustained profitability remains a key risk. With gross profit margins stabilizing and strategic pivots underway, the outlook is cautiously bullish, contingent on execution of U.S. expansion and operational efficiency gains.